 |
|
Potential Public Health Impact of Age-Related Eye Disease Study Results
AREDS Report No. 11
Age-Related Eye Disease Study Research Group*
Arch Ophthalmol. 2003;121:1621-1624.
ABSTRACT
| |
Objective To estimate the potential public health impact of the findings of the Age-Related Eye Disease Study (AREDS) on reducing the number of persons developing advanced age-related macular degeneration (AMD) during the next 5 years in the United States.
Methods The AREDS clinical trial provides estimates of AMD progression rates and of reduction in risk of developing advanced AMD when a high-dose nutritional supplement of antioxidants and zinc is used. These results are applied to estimates of the US population at risk, to estimate the number of people who would potentially avoid advanced AMD during 5 years if those at risk were to take a supplement such as that used in AREDS.
Results An estimated 8 million persons at least 55 years old in the United States have monocular or binocular intermediate AMD or monocular advanced AMD. They are considered to be at high risk for advanced AMD and are those for whom the AREDS formulation should be considered. Of these people, 1.3 million would develop advanced AMD if no treatment were given to reduce their risk. If all of these people at risk received supplements such as those used in AREDS, more than 300 000 (95% confidence interval, 158 000-487 000) of them would avoid advanced AMD and any associated vision loss during the next 5 years.
Conclusion If people at high risk for advanced AMD received supplements such as those suggested by AREDS results, the potential impact on public health in the United States would be considerable during the next 5 years.
INTRODUCTION
IN 2001, the Age-Related Eye Disease Study (AREDS) Research Group reported a reduced risk of advanced age-related macular degeneration (AMD) (choroidal neovascularization or central geographic atrophy) and its associated vision loss for study participants with monocular intermediate AMD, binocular intermediate AMD, monocular vision loss from AMD, or monocular advanced AMD who were assigned to high-dose supplementation with antioxidants (vitamin C, vitamin E, and beta carotene) plus zinc as zinc oxide or zinc alone.1 From an individual's point of view, on the basis of these findings, the AREDS Research Group1 and others2 recommend that persons with these features, and without contraindications, should consider taking supplements such as those used in AREDS. From a public health point of view, the potential impact of these results can be assessed by estimating the number of people at least 55 years old for whom supplement treatment has been recommended. On the basis of information from the AREDS database, we can apply progression rates to advanced AMD for this population and estimate the numbers of persons who would have developed advanced AMD with or without treatment. The purpose of this article is to report that potential impact.
METHODS
ESTIMATING NUMBER AT RISK FOR DEVELOPING ADVANCED AMD
On the basis of AREDS data, persons with intermediate AMD in either eye or those with vision loss from AMD or advanced AMD in only one eye were at relatively higher risk of developing advanced AMD (compared with those with few or no drusen, the risk of advanced AMD was 18 and 43 times higher for these 2 groups, respectively).1 To determine the number of people in these higher-risk groups from all individuals in the US 2000 census at least 55 years old,3 the Eye Disease Prevalence Study (EDPS) performed a meta-analysis of 7 large population-based studies involving approximately 20 000 people inside and outside of the United States. On the basis of this analysis, the EDPS estimated the age-sex-race–specific prevalence of individuals with large drusen (greatest linear dimension,  125 µm) in one or both eyes but no advanced AMD in either eye (as a marker for monocular or binocular intermediate AMD), and of individuals with advanced AMD (from either choroidal neovascularization or geographic atrophy of the retinal pigment epithelium) in one or both eyes. For this report, the EDPS prevalence estimates for the total age group at least 55 years old were used, rather than age-specific estimates. Data with respect to race were directly estimated for non-Hispanic whites and non-Hispanic blacks. Data for all other races were estimated to be the average prevalence for non-Hispanic whites and non-Hispanic blacks, since the prevalence data on Hispanics were judged to be too sparse, and since there were no other US prevalence data on American Indians, Alaskan natives, Asian Americans, Native Hawaiians, other Pacific Islanders, multiracial individuals, and all others.
Because identification of individuals with advanced AMD in the EDPS did not differentiate those with monocular advanced AMD from those with binocular advanced AMD, the proportion with monocular and binocular advanced AMD was estimated on the basis of an approximation of the proportion of individuals with monocular or binocular advanced AMD from the Beaver Dam Eye Study4 and the Baltimore Eye Survey.5 From these studies, two thirds of persons reported to have advanced AMD were estimated to have monocular advanced AMD.
Identification of individuals with geographic atrophy in the EDPS did not differentiate those with central geographic atrophy from those with geographic atrophy not involving the center of the retina. These proportions were determined from the proportion of individuals with central vs noncentral geographic atrophy in AREDS. Grading of baseline AREDS photographs demonstrated that approximately 50% of participants with geographic atrophy at baseline had the center of the retina involved by the atrophy. On the basis of this observation, we assumed that approximately 50% of persons estimated to have geographic atrophy in the EDPS had the center involved.
PROGRESSION RATES TO ADVANCED AMD
Five-year progression rates to advanced AMD in the absence of supplementation of antioxidants plus zinc, such as that used in AREDS, for individuals at least 55 years old in the United States in 2000 with monocular intermediate AMD (6.3%), binocular intermediate AMD (26.4%), and monocular advanced AMD (43.0%) were based on progression rates for individuals with these characteristics in AREDS assigned to a placebo.1
ESTIMATING RISK REDUCTION
The risk of progressing to advanced AMD, for individuals with monocular intermediate AMD, binocular intermediate AMD, or monocular advanced AMD, was presumed to be reduced by the same amount with use of a supplement of antioxidants plus zinc such as that used in AREDS. There may be some differences in these rates, but the AREDS data do not show any statistically significant differences in the treatment effect between these groups. Without clear evidence of a difference, assuming one treatment effect seems appropriate.
RESULTS
ESTIMATING NUMBER AT RISK FOR DEVELOPING ADVANCED AMD
The US Census Bureau indicates that there were 59 266 437 individuals at least 55 years old in the United States in 2000. On the basis of race-specific prevalence of neovascular AMD (Table 1) from the EDPS (assuming the prevalence for Hispanics and races other than non-Hispanic whites and non-Hispanic blacks was the average of the prevalence for non-Hispanic whites and non-Hispanic blacks), a total of 1 023 000 individuals at least 55 years old in the United States were estimated to have neovascular AMD, of whom approximately two thirds, or 685 000, were estimated to have monocular neovascular AMD and have a fellow eye at high risk of developing advanced AMD (Table 2). In addition, 824 000 were estimated to have geographic atrophy (Table 1), of whom one half, or 412 000, had cases involving the center. Of these 412 000, approximately two thirds, or 275 000, had only one eye involved with geographic atrophy (Table 2) and thus had a fellow eye at high risk of developing advanced AMD. Thus, we estimated that approximately 1 million (960 000) individuals had monocular advanced AMD (Table 2).
|
|
|
|
Table 1. Estimated Prevalence of AMD by Stage in Individuals at Least 55 Years Old in the United States From 2000 Census and Eye Disease Prevalence Study*
|
|
|
|
|
|
|
Table 2. Estimated Number of Individuals in the United States at Least 55 Years Old Considered to Be at High Risk for Advanced AMD in 2000
|
|
|
The remaining 412 000 individuals with geographic atrophy not involving the foveal center are at high risk for developing advanced AMD in either eye, including two thirds (275 000) who were estimated to have this noncentral atrophy in one eye and one third (137 000) who were estimated to have this noncentral atrophy in both eyes. In addition to the 137 000 with binocular noncentral geographic atrophy, 2 131 000 were estimated to have binocular intermediate AMD (Table 1), for a total of 2 268 000 with binocular intermediate AMD or binocular noncentral geographic atrophy at high risk for developing advanced AMD (Table 2). Furthermore, in addition to the 275 000 with monocular noncentral geographic atrophy, 4 542 000 individuals were estimated to have monocular intermediate AMD (Table 1), for a total of 4 817 000 with monocular intermediate AMD or monocular noncentral geographic atrophy at high risk for advanced AMD (Table 2). Thus, on the basis of the US census for 2000 and the EDPS, 960 000 individuals with monocular advanced AMD, 2 268 000 with binocular intermediate AMD or binocular noncentral geographic atrophy, and 4 817 000 with monocular intermediate AMD or monocular noncentral geographic atrophy, for a total of 8 045 000 individuals at least 55 years old, were estimated to be at high risk for developing advanced AMD in the United States (Table 2).
NUMBER EXPECTED TO PROGRESS TO ADVANCED AMD FROM 2000 TO 2005
In AREDS, 43% of individuals with monocular advanced AMD developed advanced AMD in the second eye within 5 years. With the use of this estimate, of the 960 000 individuals with monocular advanced AMD, a total of 413 000 will develop advanced AMD within 5 years. In addition, of the 2 266 000 individuals with binocular intermediate AMD or binocular noncentral geographic atrophy, an estimated 26.4% will develop advanced AMD within 5 years, for a total of 598 000. Finally, of the 4 818 000 individuals with monocular intermediate AMD or monocular noncentral geographic atrophy, an estimated 6.3% will develop advanced AMD within 5 years, for a total of 304 000. Thus, an estimated total of 1 315 000 individuals at least 55 years old in the United States will develop advanced AMD within 5 years (Table 3).
|
|
|
|
Table 3. Summary of Potential Public Health Impact of AREDS
|
|
|
INDIVIDUALS AVOIDING PROGRESSION TO ADVANCED AMD WITH USE OF SUPPLEMENT OF ANTIOXIDANTS PLUS ZINC
The AREDS results suggested that persons with intermediate AMD, or with advanced AMD in one eye, who used the AREDS combination formulation (antioxidants plus zinc), reduced their 5-year risk of developing advanced AMD by approximately 25% (95% confidence interval, 12%-37%). Therefore, 25% of the 1 315 000 individuals who were estimated to develop advanced AMD within 5 years, or 329 000 individuals (95% confidence interval, 158 000-487 000), will avoid developing advanced AMD if all 8 million individuals at least 55 years old who were estimated to be at high risk for developing advanced AMD in the United States take these supplements (Table 3). For the 413 000 individuals with monocular advanced AMD who will develop advanced AMD within 5 years in the second eye in the absence of an antioxidant plus zinc supplementation, approximately 103 000 (95% confidence interval, 50 000-153 000) would avoid developing advanced AMD within this period if they used the AREDS combination formulation, assuming a risk reduction of approximately 25% (95% confidence interval, 12%-37%).
COMMENT
While avoiding the development of advanced AMD—with its attendant likelihood of vision loss—in 329 000 persons during 5 years has major public health impact, this information must be considered to have major potential public health impact because of the numerous assumptions, large and small, used to derive these numbers. For example, it is unknown whether markedly different numbers would be obtained if age-specific prevalence and progression rates were used. Although age-specific prevalence is available from the EDPS, no precise information on age-specific progression rates can be obtained from AREDS. Second, it is unknown at this time if there are differential effects of reducing the risk of developing advanced AMD depending on whether an individual has monocular advanced AMD, binocular intermediate AMD or noncentral geographic atrophy, or monocular intermediate AMD or noncentral geographic atrophy, although there is no strong biological rationale at this time to suspect that there may be a differential effect. Third, it is unlikely that all individuals at high risk for advanced AMD would take the recommended supplement because of medical complications, intolerance, or noncompliance. Also, study participants may have been more compliant with medication use than one would expect in the general population. Finally, as shown by the use of confidence intervals around the treatment effect estimate, the real number people avoiding advanced AMD is highly dependent on the actual treatment effect, for which only a "best estimate" can be provided.
Avoiding the development of advanced AMD can have a major effect on the quality of life for an individual. Preventing this development in the first eye of an individual is important, since the second eye will also be at risk; preventing this development in the second eye of an individual will have a direct effect on that individual's visual function for central visual tasks and thus on that individual's quality of life. Therefore, if even half of the individuals at high risk for advanced AMD were identified and compliant with the recommended supplement, it is likely that more than 150 000 individuals would avoid vision loss for some time. These data suggest that the recommendation of such a supplement for those individuals should have a major impact on them as well as on the public health.
AUTHOR INFORMATION
Corresponding author and reprints: AREDS Coordinating Center, The EMMES Corp, 401 N Washington St, Suite 700, Rockville, MD 20850-1707 (e-mail: aredspub{at}emmes.com).
Submitted for publication November 13, 2002; final revision received April 10, 2003; accepted May 14, 2003.
This study was supported by contracts from the National Eye Institute, National Institutes of Health, Bethesda, Md, with additional support from Bausch & Lomb Inc, Rochester, NY.
*The Writing Team for the Age-Related Eye Disease Study (AREDS) Research Group consists of Neil M. Bressler, MD; Susan B. Bressler, MD; Nathan G. Congdon, MD; Frederick L. Ferris III, MD; David S. Friedman, MD; Ronald Klein, MD; Anne S. Lindblad, PhD; Roy C. Milton, PhD; and Johanna M. Seddon, MD. A complete list of the members of the AREDS Research Group appears in Arch Ophthalmol 2001;119:1434. The Writing Team for this report and the AREDS investigators have no relevant financial interest in this article.
REFERENCES
1. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS Report No. 8. Arch Ophthalmol. 2001;119:1417-1436.
FREE FULL TEXT
2. Preferred Practice Pattern. Age-related macular degeneration. American Academy of Ophthalmology Web site. Available at: http://www.aao.org/aao/education/library/ppp/loader.cfm?url=/commonspot/security/getfile.cfm&PageID=23357.
3. DP-1: Profile of General Demographic Characteristics: 2000. US Census Bureau Web site. Available at: http://factfinder.census.gov/bf/_lang=en _vt_name=DEC_2000_SF1_U_DP1_geo_id=01000US.html. Accessed August 29, 2002.
4. Klein R, Klein BEK, Linton KLP. Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 1992;99:933-943.
ISI
| PUBMED
5. Friedman DS, Katz J, Bressler NM, Rahmani B, Tielsch JM. Racial differences in the prevalence of age-related macular degeneration: the Baltimore Eye Survey. Ophthalmology. 1999;106:1049-1055.
FULL TEXT
|
ISI
| PUBMED
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
AREDS—Two Years Later
Lee M. Jampol
Arch Ophthalmol. 2003;121(11):1634-1636.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Responsiveness of NEI VFQ-25 to Changes in Visual Acuity in Neovascular AMD: Validation Studies from Two Phase 3 Clinical Trials
Suner et al.
IOVS 2009;50:3629-3635.
ABSTRACT
| FULL TEXT
Quantitative Subanalysis of Cystoid Spaces and Outer Nuclear Layer Using Optical Coherence Tomography in Age-Related Macular Degeneration
Kashani et al.
IOVS 2009;50:3366-3373.
ABSTRACT
| FULL TEXT
Effects of Dioxin on Vascular Endothelial Growth Factor (VEGF) Production in the Retina Associated with Choroidal Neovascularization
Takeuchi et al.
IOVS 2009;50:3410-3416.
ABSTRACT
| FULL TEXT
Systemic bevacizumab (Avastin) therapy for exudative neovascular age-related macular degeneration. The BEAT-AMD-Study
Schmid-Kubista et al.
Br J Ophthalmol 2009;93:914-919.
ABSTRACT
| FULL TEXT
Visualization of Sub-retinal Pigment Epithelium Morphologies of Exudative Macular Diseases by High-Penetration Optical Coherence Tomography
Yasuno et al.
IOVS 2009;50:405-413.
ABSTRACT
| FULL TEXT
A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration
Arias et al.
Br J Ophthalmol 2008;92:1636-1641.
ABSTRACT
| FULL TEXT
Quantitative Optical Coherence Tomography Findings in Various Subtypes of Neovascular Age-Related Macular Degeneration
Liakopoulos et al.
IOVS 2008;49:5048-5054.
ABSTRACT
| FULL TEXT
Quantitative Subanalysis of Optical Coherence Tomography after Treatment with Ranibizumab for Neovascular Age-Related Macular Degeneration
Keane et al.
IOVS 2008;49:3115-3120.
ABSTRACT
| FULL TEXT
Age-Related Macular Degeneration
Jager et al.
NEJM 2008;358:2606-2617.
FULL TEXT
Racial Differences and Other Risk Factors for Incidence and Progression of Age-Related Macular Degeneration: Salisbury Eye Evaluation (SEE) Project
Chang et al.
IOVS 2008;49:2395-2402.
ABSTRACT
| FULL TEXT
Gene-environment interaction in progression of AMD: the CFH gene, smoking and exposure to chronic infection
Baird et al.
Hum Mol Genet 2008;17:1299-1305.
ABSTRACT
| FULL TEXT
Foveal Cone-Photoreceptor Integrity in Aging Macula Disorder
Kanis et al.
IOVS 2008;49:2077-2081.
ABSTRACT
| FULL TEXT
Improved Vision-Related Function After Ranibizumab Treatment of Neovascular Age-Related Macular Degeneration: Results of a Randomized Clinical Trial
Chang et al.
Arch Ophthalmol 2007;125:1460-1469.
ABSTRACT
| FULL TEXT
Genetic Associations With Age-Related Macular Degeneration
Damian
JAMA 2007;298:1637-1637.
FULL TEXT
Dietary carbohydrate and the progression of age-related macular degeneration: a prospective study from the Age-Related Eye Disease Study
Chiu et al.
Am. J. Clin. Nutr. 2007;86:1210-1218.
ABSTRACT
| FULL TEXT
Incident Choroidal Neovascularization in Fellow Eyes of Patients With Unilateral Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration: SST Report No. 20 From the Submacular Surgery Trials Research Group
Submacular Surgery Trials Research Group
Arch Ophthalmol 2007;125:1323-1330.
ABSTRACT
| FULL TEXT
Intravitreal Bevacizumab vs Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration
Bashshur et al.
Arch Ophthalmol 2007;125:1357-1361.
ABSTRACT
| FULL TEXT
Effect of systemic bevacizumab therapy on retinal pigment epithelial detachment
Bolz et al.
Br J Ophthalmol 2007;91:785-789.
ABSTRACT
| FULL TEXT
Scavenger Receptors for Oxidized Lipoprotein in Age-Related Macular Degeneration
Kamei et al.
IOVS 2007;48:1801-1807.
ABSTRACT
| FULL TEXT
Light Induces Programmed Cell Death by Activating Multiple Independent Proteases in a Cone Photoreceptor Cell Line
Kanan et al.
IOVS 2007;48:40-51.
ABSTRACT
| FULL TEXT
Potential value of antioxidant-rich foods in slowing age-related macular degeneration.
Mares
Arch Ophthalmol 2006;124:1339-1340.
FULL TEXT
Hormone Therapy and Age-Related Macular Degeneration: The Women's Health Initiative Sight Exam Study
Haan et al.
Arch Ophthalmol 2006;124:988-992.
ABSTRACT
| FULL TEXT
A 76-year-old man with macular degeneration.
Arroyo
JAMA 2006;295:2394-2406.
FULL TEXT
Progression of Age-Related Macular Degeneration: Prospective Assessment of C-Reactive Protein, Interleukin 6, and Other Cardiovascular Biomarkers
Seddon et al.
Arch Ophthalmol 2005;123:774-782.
ABSTRACT
| FULL TEXT
Nuclear Gene Expression Changes Due to Mitochondrial Dysfunction in ARPE-19 Cells: Implications for Age-Related Macular Degeneration
Miceli and Jazwinski
IOVS 2005;46:1765-1773.
ABSTRACT
| FULL TEXT
Photodynamic Therapy With Verteporfin: Observations on the Introduction of a New Treatment Into Clinical Practice
Schein et al.
Arch Ophthalmol 2005;123:58-63.
ABSTRACT
| FULL TEXT
Pegaptanib for Neovascular Age-Related Macular Degeneration
Gragoudas et al.
NEJM 2004;351:2805-2816.
ABSTRACT
| FULL TEXT
Age-Related Macular Degeneration Is the Leading Cause of Blindness . . .
Bressler
JAMA 2004;291:1900-1901.
FULL TEXT
Special Considerations in the Guidelines for High-Dose Vitamin Supplementation in Patients With Age-Related Macular Degeneration--Reply
Ferris and Milton
Arch Ophthalmol 2004;122:662-663.
FULL TEXT
Age-related macular degeneration: armed against ARMD
Weir
CMAJ 2004;170:463-464.
FULL TEXT
AREDS--Two Years Later
Jampol
Arch Ophthalmol 2003;121:1634-1636.
FULL TEXT
|
